**Suplementary table 1.** analysis of patients with immunosuppression according to the study definition

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Variable | All patients(n= 102) | Patients<85 years(n=86) | Patients≥85 years(n=16) | p-value |
| Cancer | 42/102 (41.2%) | 36/86 (41.9%) | 6/16 (37.5%) | 0.74 |
| Active cancer  | 37/42 (88.1%) | 34/36 (94.4%) | 3/6 (56%) | 0.01 |
| Location of cancer (n=42) |  |  |  |  |
| Head and neck | 1 (2.4%) | 1 (2.8%) | 0 |  |
| Lung | 9 (24.4%) | 9 (25%) | 0 |  |
| Digestive | 9 (21.4%) | 8 (22.2%) | 1 (16.7) |  |
| Breast | 2 (4.8%) | 2 (5.6%) | 0 |  |
| Prostate | 2 (4.8%) | 2 (5.6%) | 0 |  |
| Gynaecological | 2 (4.8%) | 2 (5.6%) | 0 |  |
| Myeloproliferative | 12 (25.6%) | 8 (22.2%) | 4 (66.7%) |  |
| Skin | 2 (4.8%) | 1 (2.8%) | 1 (16.7%) |  |
| Other | 3 (7.1%) | 3 (8.3%) | 0 |  |
| Active treatment  | 32/42 (76.2%) | 28/36 (77.8%) | 4/6 (66.7%) | 0.61 |
| Type of treatment |  |  |  |  |
| Chemotherapy | 18 (56.3%) | 15 (53.6%) | 3 (75%) |  |
| Radiotherapy | 7 (21.9%) | 7 (25%) | 0 |  |
| Immunotherapy | 5 (15.6%) | 4 (14.3%) | 1 (25%) |  |
| Hormonetherapy | 1 (3.1%) | 1 (3.6%) | 0 |  |
| Other | 1 (1.3%) | 1 (3.6%) | 0 |  |
| Cancer diagnosis (years) | 3.13 (1.67-5.03) | 3.13 (1.66-4.99) | 3.63 (1.44-10.58) | 0.64 |
| Systemic autoimmune diasease | 23/102 (22.05%) | 19/86 (22.1%) | 4/16 (25%) | 0.75 |
| Type of AD\* |  |  |  |  |
| Sarcoidosis | 1 (4.3%) | 1 (5.3%) | 0 |  |
| SLE\*\* | 1 (4.3%) | 1 (5.3%) | 0 |  |
| Giant cell arteritis | 2 (8.7%) | 1 (5.3%) | 1 (25%) |  |
| Rheumatoid arthritis | 8 (34.8%) | 7 (36.8%) | 1 (25%) |  |
| Polymyalgia rheumatica | 8 (34.8%) | 7 (36.8%) | 1 (25%) |  |
| Scleroderma | 1 (4.3%) | 1 (5.3%) | 0 |  |
| Others  | 2 (8.7%) | 1 (5.3%) | 1 (25%) |  |
| Active treatment | 22/23 (95.7%) | 18/19 (94.7%) | 4/4 (100%) | 1 |
| AD diagnosis (years) | 4.11 (1.49-9.62) | 4.08 (1.49-10.09) | 4.64 (1.64-8.83) | 0.93 |
| Other immunosupresion |  |  |  |  |
| HIV | 9/102 (8.82%) | 9/86 (10.5%) | 0/16 |  |
| Transplantation | 17/102 (16.6%) | 15/86 (17.4%) | 2/16 (12.5%) |  |
| Other\*\*\*  | 14/102 (13.72%) | 7/86 (8.14%) | 4/16 (25%) |  |
| Use of steroidΨ | 55/509 (10.8%) | 46/392 (11.7%) | 9/117 (7.7%) | 0.21 |

\* SLE Systemic Lupus Erythematosus

\*\* AD Autoimmune diseases

\*\*\* Including other causes of steroid use

Ψvariable calculated on the total sample of patients